Cargando…

A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells

HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Rindler, Audrey E., Kuster, Herbert, Neumann, Kathrin, Leemann, Christine, Braun, Dominique L., Metzner, Karin J., Günthard, Huldrych F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000554/
https://www.ncbi.nlm.nih.gov/pubmed/33806576
http://dx.doi.org/10.3390/v13030404
_version_ 1783671024746758144
author Rindler, Audrey E.
Kuster, Herbert
Neumann, Kathrin
Leemann, Christine
Braun, Dominique L.
Metzner, Karin J.
Günthard, Huldrych F.
author_facet Rindler, Audrey E.
Kuster, Herbert
Neumann, Kathrin
Leemann, Christine
Braun, Dominique L.
Metzner, Karin J.
Günthard, Huldrych F.
author_sort Rindler, Audrey E.
collection PubMed
description HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have been established. However, there is still demand for a high throughput replication capacity assay using primary cells which is robust and reproducible. In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSF(WT) and HIV-1 JR-CSF(K65R_M184V). Replication capacity was determined by measuring the viral growth on PBMCs over 10 days by longitudinally transferring cell culture supernatant to TZM-bl reporter cells. By utilizing the TZM-bl luciferase reporter assay, we determined replication capacity by measuring viral infectivity. The simplicity of the experimental setup allowed for all 346 primary HIV-1 isolates to be replicated at one time. Although the infectious input dose for each virus was normalized, a broad range of replication capacity values over 4 logs was observed. The approach was confirmed by two repeated experiments and we demonstrated that the reproducibility of the replication capacity values is statistically comparable between the two separate experiments. In summary, these results endorse our high throughput replication capacity assay as reproducible and robust and can be utilized for large scale HIV-1 replication capacity experiments in primary cells.
format Online
Article
Text
id pubmed-8000554
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80005542021-03-28 A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells Rindler, Audrey E. Kuster, Herbert Neumann, Kathrin Leemann, Christine Braun, Dominique L. Metzner, Karin J. Günthard, Huldrych F. Viruses Article HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have been established. However, there is still demand for a high throughput replication capacity assay using primary cells which is robust and reproducible. In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSF(WT) and HIV-1 JR-CSF(K65R_M184V). Replication capacity was determined by measuring the viral growth on PBMCs over 10 days by longitudinally transferring cell culture supernatant to TZM-bl reporter cells. By utilizing the TZM-bl luciferase reporter assay, we determined replication capacity by measuring viral infectivity. The simplicity of the experimental setup allowed for all 346 primary HIV-1 isolates to be replicated at one time. Although the infectious input dose for each virus was normalized, a broad range of replication capacity values over 4 logs was observed. The approach was confirmed by two repeated experiments and we demonstrated that the reproducibility of the replication capacity values is statistically comparable between the two separate experiments. In summary, these results endorse our high throughput replication capacity assay as reproducible and robust and can be utilized for large scale HIV-1 replication capacity experiments in primary cells. MDPI 2021-03-04 /pmc/articles/PMC8000554/ /pubmed/33806576 http://dx.doi.org/10.3390/v13030404 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Rindler, Audrey E.
Kuster, Herbert
Neumann, Kathrin
Leemann, Christine
Braun, Dominique L.
Metzner, Karin J.
Günthard, Huldrych F.
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
title A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
title_full A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
title_fullStr A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
title_full_unstemmed A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
title_short A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
title_sort novel high throughput, parallel infection assay for determining the replication capacities of 346 primary hiv-1 isolates of the zurich primary hiv-1 infection study in primary cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000554/
https://www.ncbi.nlm.nih.gov/pubmed/33806576
http://dx.doi.org/10.3390/v13030404
work_keys_str_mv AT rindleraudreye anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT kusterherbert anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT neumannkathrin anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT leemannchristine anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT braundominiquel anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT metznerkarinj anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT gunthardhuldrychf anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT rindleraudreye novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT kusterherbert novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT neumannkathrin novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT leemannchristine novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT braundominiquel novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT metznerkarinj novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells
AT gunthardhuldrychf novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells